Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Clin Immunol ; 42(1): 146-157, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34669143

RESUMEN

PURPOSE: Fatty acid (FA) abnormalities are found in various inflammatory disorders and have been related to disturbed gut microbiota. Patients with common variable immunodeficiency (CVID) have inflammatory complications associated with altered gut microbial composition. We hypothesized that there is an altered FA profile in CVID patients, related to gut microbial dysbiosis. METHODS: Plasma FAs were measured in 39 CVID patients and 30 healthy controls. Gut microbial profile, a food frequency questionnaire, and the effect of the oral antibiotic rifaximin were investigated in CVID patients. RESULTS: The n-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (EPA) (1.4 [1.0-1.8] vs. 1.9 [1.2-2.5], median (IQR), P < 0.05), and docosahexaenoic acid (DHA) (3.2 [2.4-3.9] vs. 3.5 [2.9-4.3], P < 0.05), all values expressed as weight percent of total plasma FAs, were reduced in CVID compared to controls. Also, n-6 PUFAs (34.3 ± 3.4 vs. 37.1 ± 2.8, mean ± SD, P < 0.001) and linoleic acid (LA) (24.5 ± 3.3 vs. 28.1 ± 2.7, P < 0.0001) and the FA anti-inflammatory index (98.9 [82.1-119.4] vs. 117.0 [88.7-153.1], median (IQR), P < 0.05) were reduced in CVID. The microbial alpha diversity was positively associated with plasma n-6 PUFAs (r = 0.41, P < 0.001) and LA (r = 0.51, P < 0.001), but not n-3 PUFAs (P = 0.78). Moreover, a 2-week course of rifaximin significantly reduced the proportion of n-6 PUFAs (P = 0.04, UNIANOVA). Serum immunoglobulin G (IgG) levels correlated with plasma n-3 PUFAs (rho = 0.36, P = 0.03) and DHA (rho = 0.41, P = 0.009). CONCLUSION: We found a potentially unfavorable FA profile in CVID, related to low IgG levels. High plasma n-6 PUFAs were related to increased gut microbial diversity and altered by rifaximin therapy.


Asunto(s)
Inmunodeficiencia Variable Común , Ácidos Grasos Omega-3 , Microbioma Gastrointestinal , Inmunodeficiencia Variable Común/tratamiento farmacológico , Ácidos Grasos/farmacología , Ácidos Grasos Omega-3/farmacología , Ácidos Grasos Omega-6/farmacología , Humanos
2.
Iran J Med Sci ; 46(2): 128-135, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33753957

RESUMEN

Background: One of the major indices of immunodeficiency is lymphoid organ atrophy. Some trace elements are candidates for the treatment of this defect. These conditions may induce structural changes in the sub-components of lymphoid organs. Therefore, this study evaluated the effect of selenium on volumetric changes in dexamethasone (DEX)-induced lymphoid organ atrophy in an animal model. Methods: This study was conducted at Histomorphometry and Stereology Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran, in September 2016 to September 2017. Thirty-two male rats were divided into four groups: Group I; control (normal saline, 0.5 mL/kg, intraperitoneally), Group II; DEX (0.4 mg/kg; intraperitoneally), Group III; selenium plus DEX (similar to Group II and Group IV), and Group IV; selenium (0.1 mg/kg; orally). At the end of the experiment, the rats' thymus, spleen, and lymph nodes were removed, processed, and stained by hematoxylin and eosin (H&E). The volume and volume density of theses organs were estimated by stereology. The results were analyzed using the Mann-Whitney U-test and the Kruskal-Wallis test. Results: The volume of the thymus as well as its cortex and medulla; the volume of the spleen as well as the volume density of its white pulp, periarterial lymphatic sheath zone, and follicles; and the volume of the lymph nodes as well as their inner (P=0.001) and outer (P=0.007) cortices showed a significant reduction in the DEX-treated animals in comparison with the controls. In the DEX plus selenium-treated animals, maximum effects were observed on the increment in the thymic cortex (P=0.001), the outer cortex of the lymph nodes (P=0.012), and the splenic follicles (P=0.018) in comparison with the DEX group. There was no significant difference between the animals receiving selenium treatment and the controls in terms of lymphoid organs. Conclusion: Selenium may improve lymphoid organ structures in an immunodeficiency rat model but has no effect on normal lymphoid tissues.


Asunto(s)
Inmunodeficiencia Variable Común/tratamiento farmacológico , Dexametasona/farmacología , Selenio/efectos adversos , Animales , Inmunodeficiencia Variable Común/patología , Dexametasona/farmacocinética , Modelos Animales de Enfermedad , Irán , Tejido Linfoide/efectos de los fármacos , Masculino , Ratas , Selenio/metabolismo
3.
BMJ Case Rep ; 20172017 May 27.
Artículo en Inglés | MEDLINE | ID: mdl-28551598

RESUMEN

A 57-year-old woman with frequent respiratory infections was initially diagnosed with IgG subclass deficiency based on low levels of IgG subclasses 2 and 3. Three years later, she progressed to having IgA deficiency as well. With a normal total IgG level, she does not meet criteria for common variable immunodeficiency (CVID). This may represent a variant of CVID. This also highlights the importance of immunoglobulin subclass estimation in patients where immunodeficiency is suspected clinically. She is being treated with rotational antibiotics the first 10 days of every month, monthly intravenous immunoglobulin (IVIG) infusion and osteopathic manipulation one to two times per month. On this regimen, although she has had several viral respiratory infections, she has avoided further hospitalisation for more than 1 year.


Asunto(s)
Inmunodeficiencia Variable Común/clasificación , Inmunodeficiencia Variable Común/inmunología , Antibacterianos/uso terapéutico , Inmunodeficiencia Variable Común/complicaciones , Inmunodeficiencia Variable Común/tratamiento farmacológico , Diagnóstico Diferencial , Femenino , Humanos , Deficiencia de IgA , Deficiencia de IgG , Inmunoglobulinas Intravenosas/uso terapéutico , Persona de Mediana Edad , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Infecciones del Sistema Respiratorio/etiología , Infecciones del Sistema Respiratorio/inmunología , Resultado del Tratamiento
4.
Rev Alerg Mex ; 50(5): 198-200, 2003.
Artículo en Español | MEDLINE | ID: mdl-14631592

RESUMEN

A case with common variable immunodeficiency associated to hyperprolactinaemia and severe damage of mucosal defenses is reported, in which humoral and cellular response was widely explored. The impact of the cytokines therapy was analyzed as complementary schedule to the conventional therapy with gammaglobuline. Immune response to the treatment was long-time evaluated in relation with therapeutic interventions. Combination of alpha 2 b-IFN, thymic factors, gammaglobuline and GM-CSF was a good alternative to treat complicated common variable immunodeficiency.


Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Inmunodeficiencia Variable Común/tratamiento farmacológico , Factor Estimulante de Colonias de Granulocitos y Macrófagos/uso terapéutico , Hiperprolactinemia/complicaciones , Interferón-alfa/uso terapéutico , Ácido Pirrolidona Carboxílico/análogos & derivados , Ácido Pirrolidona Carboxílico/uso terapéutico , Tiazoles/uso terapéutico , Factor de Transferencia/uso terapéutico , gammaglobulinas/uso terapéutico , 2-Piridinilmetilsulfinilbencimidazoles , Adulto , Antibacterianos/uso terapéutico , Bencimidazoles/uso terapéutico , Bromocriptina/uso terapéutico , Inmunodeficiencia Variable Común/complicaciones , Quimioterapia Combinada , Femenino , Humanos , Hiperprolactinemia/tratamiento farmacológico , Interferón alfa-2 , Mesalamina/uso terapéutico , Omeprazol/análogos & derivados , Rabeprazol , Ranitidina/uso terapéutico , Proteínas Recombinantes , Tiazolidinas , Vitaminas/uso terapéutico
5.
J Clin Lab Immunol ; 49(1): 41-5, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9819672

RESUMEN

The authors present a case of a patient who developed recurrent bacterial upper respiratory and pulmonary infections and marked hypogammaglobulinemia with a gradual decrease of serum IgG, IgA and IgM some months after acute Epstein-Barr virus infection. Test for identification of lymphocyte subpopulation showed increased CD8+ T-cells with a surface phenotype (CD8+, CD57+, HLA-DR+) characteristic of virus-induced, activated cytotoxic cells. Viral investigations showed a positive anti-EBNA titer, an IgG titer anti-VCA of 1:40, a negative IgG titer anti-EA and human immunodeficiency virus negativity. The authors conclude that these clinical features are indicative of possible common variable immunodeficiency following Epstein-Barr virus infection.


Asunto(s)
Inmunodeficiencia Variable Común/etiología , Mononucleosis Infecciosa/complicaciones , Adyuvantes Inmunológicos/uso terapéutico , Adulto , Agammaglobulinemia/etiología , Anticuerpos Antivirales/sangre , Infecciones Bacterianas/etiología , Cimetidina/uso terapéutico , Inmunodeficiencia Variable Común/tratamiento farmacológico , Antígenos Nucleares del Virus de Epstein-Barr/inmunología , Herpesvirus Humano 4/inmunología , Humanos , Mononucleosis Infecciosa/inmunología , Recuento de Linfocitos , Subgrupos Linfocitarios , Masculino , Recurrencia , Infecciones del Sistema Respiratorio/etiología , Sulfato de Zinc/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA